Bortezomid In Combination With Chemotherapy In The Treatment Of Relapsed Or Refractory Multiple Myeloma

Objective:To investigate the efficacy and security of bortezomid combined with chemotherapy in the treatment of patients with relapsed or refractory multiple myeloma.Methods:11 patients(male/female is 7/4,mean age is 60.36 years)with refractory or relapsed myeloma had been treated with bortezomid 0.7-1.3mg/m~2 on days 1,4,8,11 in two week cycle,and the same time following chemotherapy.The patients had received one to four cycles at least.Response to bortezomid was evaluated according to the criteria of the Bladébefore initiation of each bortezomid chemotherapy cycle. Adverse events was graded according to the National Cancer Institute Common Toxicity Criteria,Version 3.0.Results:The media follow-up from the start of bortezomid treatment was 15 months. A clinical response was observed in 9 patients(81.8%),Including near complete response in 6 patients,partial response in 2 patients,minimal response in 1 patient, and no change in 2 patients.The most common adverse events were gastrointestinal symptoms,thrombocytopenia,peripheral neuropathy,fatigue.All adverse events were manageable with roution support.Conclusion:Bortezomid combined with chemotherapy is a new effective therapy in patients with relapse or refractory myeloma which with a high response rate and manageable toxicities.